Related Experiment Videos
Pramlintide reduces the risks associated with glucose variability in type 1 diabetes
Boris P Kovatchev1, John Crean, Anthony McCall
1University of Virginia Health System, Charlottesville, Virginia 22901, USA. boris@virginia.edu
Diabetes Technology & Therapeutics
|August 22, 2008
Summary
Pramlintide significantly reduced blood glucose (BG) fluctuations in type 1 diabetes patients, lowering post-meal hyperglycemia without increasing hypoglycemia risk. This therapy helps manage extreme BG variations when added to insulin.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 1 diabetes management often involves insulin therapy.
- Extreme blood glucose (BG) fluctuations pose significant health risks.
- Controlling postprandial hyperglycemia and hypoglycemia is crucial.
Purpose of the Study:
- To evaluate if pramlintide, when added to insulin therapy, reduces extreme BG fluctuations in type 1 diabetes.
- To assess the impact of pramlintide on the rate and magnitude of BG changes.
- To determine if pramlintide affects the risk of hypoglycemia.
Main Methods:
- Retrospective analysis of self-monitored BG (SMBG) data from a randomized, double-blind, placebo-controlled trial.
- Comparison between pramlintide (30/60 microg) and placebo groups (n=119 vs. n=129).
- Calculation of daily BG profiles, BG rate of change, and high/low BG indices (HBGI/LBGI).
Main Results:
- Pramlintide significantly attenuated the pre- to postprandial BG rate of change compared to placebo (P<0.0001).
- Pramlintide treatment led to significantly lower average post-meal BG and postprandial HBGI (P<0.0001).
- Reduced BG variation was observed in pramlintide patients without an increased LBGI (hypoglycemia risk).
Conclusions:
- Pramlintide treatment demonstrated risk-reduction effects on BG fluctuations, independent of average glycemia changes.
- Key benefits include reduced rate and magnitude of postprandial BG fluctuations.
- These glycemic control improvements were achieved without a concurrent increase in hypoglycemia risk.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...